- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Journal of Oncology
Volume 2012 (2012), Article ID 934918, 7 pages
Vascular Disrupting Agent Arsenic Trioxide Enhances Thermoradiotherapy of Solid Tumors
1Department of Radiation Oncology, University of Arkansas for Medical Sciences, 4301 W. Markham Street, Slot No. 824, Little Rock, AR 72205, USA
2Department of Mechanical Engineering and Therapeutic Radiology, University of Minnesota, 240 Delaware Street, SE Slot No. 494, Minneapolis, MN 55455, USA
Received 3 June 2011; Revised 23 August 2011; Accepted 6 September 2011
Academic Editor: Sundaram Ramakrishnan
Copyright © 2012 Robert J. Griffin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- J. Fang, S. J. Chen, J. H. Tong, Z. G. Wang, G. Q. Chen, and Z. Chen, “Treatment of acute promyelocytic leukemia with ATRA and As2O3: a model of molecular target-based cancer therapy,” Cancer Biology & Therapy, vol. 1, no. 6, pp. 614–620, 2002.
- X. Cai, Y. Yu, Y. Huang et al., “Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells,” Leukemia, vol. 17, no. 7, pp. 1333–1337, 2003.
- A. M. Evens, M. S. Tallman, and R. B. Gartenhaus, “The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future,” Leukemia Research, vol. 28, no. 9, pp. 891–900, 2004.
- W. H. Miller Jr., H. M. Schipper, J. S. Lee, J. Singer, and S. Waxman, “Mechanisms of action of arsenic trioxide,” Cancer Research, vol. 62, no. 14, pp. 3893–3903, 2002.
- W. H. Miller Jr., “Molecular targets of arsenic trioxide in malignant cells,” Oncologist, vol. 7, supplement 1, pp. 14–19, 2002.
- S. L. Soignet, P. Maslak, Z. G. Wang et al., “Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide,” The New England Journal of Medicine, vol. 339, no. 19, pp. 1341–1348, 1998.
- Y. S. Lew, S. L. Brown, R. J. Griffin, C. W. Song, and J. H. Kim, “Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown,” Cancer Research, vol. 59, no. 24, pp. 6033–6037, 1999.
- R. J. Griffin, S. H. Lee, K. L. Rood et al., “Use of arsenic trioxide as an antivascular and thermosensitizing agent in solid tumors,” Neoplasia, vol. 2, no. 6, pp. 555–560, 2000.
- R. J. Griffin, H. Monzen, B. W. Williams, H. Park, S. H. Lee, and C. W. Song, “Arsenic trioxide induces selective tumour vascular damage via oxidative stress and increases thermosensitivity of tumours,” International Journal of Hyperthermia, vol. 19, no. 6, pp. 575–589, 2003.
- R. J. Griffin, B. W. Williams, H. J. Park, and C. W. Song, “Preferential action of arsenic trioxide in solid-tumor microenvironment enhances radiation therapy,” International Journal of Radiation Oncology Biology Physics, vol. 61, no. 5, pp. 1516–1522, 2005.
- J. H. Kim, Y. S. Lew, A. Kolozsvary, S. Ryu, and S. L. Brown, “Arsenic trioxide enhances radiation response of 9L glioma in the rat brain,” Radiation Research, vol. 160, no. 6, pp. 662–666, 2003.
- Y. S. Lew, A. Kolozsvary, S. L. Brown, and J. H. Kim, “Synergistic interaction with arsenic trioxide and fractionated radiation in locally advanced murine tumor,” Cancer Research, vol. 62, no. 15, pp. 4202–4205, 2002.
- R. W. Ahn, F. Chen, H. Chen et al., “A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer,” Clinical Cancer Research, vol. 16, no. 14, pp. 3607–3617, 2010.
- H. Chen, R. Ahn, J. van den Bossche, D. H. Thompson, and T. V. O'Halloran, “Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide,” Molecular Cancer Therapeutics, vol. 8, no. 7, pp. 1955–1963, 2009.
- H. Monzen, R. J. Griffin, B. W. Williams, M. Amano, S. Ando, and T. Hasegawa, “Study of arsenic trioxide-induced vascular shutdown and enhancement with radiation in solid tumor,” Radiation Medicine, vol. 22, no. 4, pp. 205–211, 2004.
- A. M. Westermann, E. L. Jones, B. C. Schem et al., “First results of triple-modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with stage IIB, III, and IVA cervical carcinoma,” Cancer, vol. 104, no. 4, pp. 763–770, 2005.
- J. W. J. Bergs, N. A. P. Franken, J. Haveman, E. D. Geijsen, J. Crezee, and C. van Bree, “Hyperthermia, cisplatin and radiation trimodality treatment: a promising cancer treatment? A review from preclinical studies to clinical application,” International Journal of Hyperthermia, vol. 23, no. 4, pp. 329–341, 2007.
- N. E. Hoffmann and J. C. Bischof, “Cryosurgery of normal and tumor tissue in the dorsal skin flap chamber: part I—thermal response,” Journal of Biomechanical Engineering, vol. 123, no. 4, pp. 301–309, 2001.
- V. S. Kalambur, H. Mahaseth, J. C. Bischof, et al., “Microvascular blood flow and stasis in transgenic sickle mice: utility of a dorsal skin fold chamber for intravital microscopy,” American Journal of Hematology, vol. 77, no. 2, pp. 117–125, 2004.
- S. Bhowmick, N. E. Hoffmann, and J. C. Bischof, “Thermal therapy of prostate tumor tissue in the dorsal skin flap chamber,” Microvascular Research, vol. 64, no. 1, pp. 170–173, 2002.
- R. J. Griffin, B. W. Williams, J. C. Bischof, M. Olin, G. L. Johnson, and B. W. Lee, “Use of a fluorescently labeled poly-caspase inhibitor for in vivo detection of apoptosis related to vascular-targeting agent arsenic trioxide for cancer therapy,” Technology in Cancer Research and Treatment, vol. 6, no. 6, pp. 651–654, 2007.
- J. Bernier, J. Denekamp, A. Rojas et al., “ARCON: accelerated radiotherapy with carbogen and nicotinamide in non small cell lung cancer: a phase I/II study by the EORTC,” Radiotherapy and Oncology, vol. 52, no. 2, pp. 149–156, 1999.
- W. C. Dewey, “Interaction of heat with radiation and chemotherapy,” Cancer Research, vol. 44, no. 10, pp. 4714s–4720s, 1984.
- M. R. Horsman, D. J. Chaplin, and J. Overgaard, “Combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumor cells,” Cancer Research, vol. 50, no. 23, pp. 7430–7436, 1990.
- M. Bischof, A. Abdollahi, P. Gong et al., “Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells,” International Journal of Radiation Oncology Biology Physics, vol. 60, no. 4, pp. 1220–1232, 2004.
- T. S. Herman and B. A. Teicher, “Sequencing of trimodality therapy [cis-diamminedichloroplatinum(II)/hyperthermia/radiation] as determined by tumor growth delay and tumor cell survival in the FSaIIC fibrosarcoma,” Cancer Research, vol. 48, no. 10, pp. 2693–2697, 1988.
- T. S. Herman, B. A. Teicher, and C. N. Coleman, “Interaction of SR-4233 with hyperthermia and radiation in the FSaIIC murine fibrosarcoma tumor system in vitro and in vivo,” Cancer Research, vol. 50, no. 16, pp. 5055–5059, 1990.
- M. R. Horsman and R. Murata, “Combination of vascular targeting agents with thermal or radiation therapy,” International Journal of Radiation Oncology Biology Physics, vol. 54, no. 5, pp. 1518–1523, 2002.
- M. R. Horsman, R. Murata, and J. Overgaard, “Improving local tumor control by combining vascular targeting drugs, mild hyperthermia and radiation,” Acta Oncologica, vol. 40, no. 4, pp. 497–503, 2001.
- R. Murata and M. R. Horsman, “Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid,” International Journal of Hyperthermia, vol. 20, no. 4, pp. 393–404, 2004.
- T. S. Herman, M. S. Jochelson, B. A. Teicher et al., “A phase I-II trial of cisplatin, hyperthermia and radiation in patients with locally advanced malignancies,” International Journal of Radiation Oncology Biology Physics, vol. 17, no. 6, pp. 1273–1279, 1989.
- T. S. Herman, B. A. Teicher, and S. A. Holden, “Trimodality therapy (drug/hyperthermia/radiation) with BCNU or mitomycin C,” International Journal of Radiation Oncology Biology Physics, vol. 18, no. 2, pp. 375–382, 1990.
- P. E. Huber, M. Bischof, J. Jenne et al., “Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy,” Cancer Research, vol. 65, no. 9, pp. 3643–3655, 2005.
- S. L. Hokland and M. R. Horsman, “The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitization,” International Journal of Hyperthermia, vol. 23, no. 7, pp. 599–606, 2007.
- R. Murata, J. Overgaard, and M. R. Horsman, “Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotheraphy,” International Journal of Radiation Oncology Biology Physics, vol. 51, no. 4, pp. 1018–1024, 2001.
- A. Hines-Peralta, V. Sukhatme, M. Regan, S. Signoretti, Z. J. Liu, and S. N. Goldberg, “Improved tumor destruction with arsenic trioxide and radiofrequency ablation in three animal models,” Radiology, vol. 240, no. 1, pp. 82–89, 2006.
- P. J. Dilda, S. Decollogne, L. Weerakoon et al., “Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol,” Journal of Medicinal Chemistry, vol. 52, no. 20, pp. 6209–6216, 2009.
- P. J. Dilda and P. J. Hogg, “Arsenical-based cancer drugs,” Cancer Treatment Reviews, vol. 33, no. 6, pp. 542–564, 2007.